The vagus nerve has become one of the most important targets in headache treatment over the past decade. Non-invasive vagus nerve stimulation (nVNS) devices now hold FDA clearance for both migraine and cluster headache, and the neuroscience behind how vagal activation interrupts headache pathways is increasingly well understood. This article covers the mechanism, the clinical evidence, and who these treatments are for.
How the Vagus Nerve Connects to Headache Pathways
Migraine and cluster headache involve activation of the trigeminovascular system — the network of trigeminal nerve fibres that innervate blood vessels in the meninges (brain coverings). When this system activates, it releases neuropeptides including CGRP (calcitonin gene-related peptide), causing neurogenic inflammation and the characteristic throbbing pain.
The vagus nerve intersects this pathway at the brainstem level. Vagal afferent fibres project to the nucleus tractus solitarius (NTS), which has direct connections to the trigeminal nucleus caudalis (TNC) — the brainstem relay for head and face pain. Stimulating vagal afferents can inhibit activity in the TNC, dampening the trigeminovascular cascade that produces headache pain. The vagus also modulates the locus coeruleus and raphe nuclei, which release noradrenaline and serotonin — neurotransmitters involved in both pain modulation and the autonomic symptoms (nausea, light sensitivity) that accompany migraines.
gammaCore: The FDA-Cleared nVNS Device
gammaCore (electroCore) is a handheld cervical nVNS device that delivers electrical stimulation through the skin of the neck over the vagus nerve. The user places the device on one side of the neck and self-administers a two-minute stimulation. It holds multiple FDA clearances:
Cluster headache (acute and preventive). The ACT1 trial demonstrated that gammaCore was significantly more effective than sham stimulation for aborting acute episodic cluster headache attacks. The ACT2 trial extended this to prevention, showing reduced attack frequency with regular daily use. These clearances (2017, 2018) made gammaCore the first non-invasive VNS device cleared for cluster headache.
Migraine (acute treatment). The PRESTO trial (2019) showed that gammaCore achieved significantly higher rates of pain freedom at 30 and 60 minutes compared to sham stimulation for acute migraine treatment. A subsequent FDA clearance in 2023 expanded the indication to acute treatment of pain associated with migraine in adults. The gammaCore Sapphire, a newer-generation device, became available in 2024.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Migraine and the Vagus Nerve
Migraine involves a complex sequence: cortical spreading depression (the aura wave), trigeminovascular activation, neurogenic inflammation, and central sensitisation. The vagus nerve appears to modulate several of these stages.
During migraine attacks, many patients experience prominent vagal symptoms — nausea, vomiting, pallor, and changes in heart rate. These reflect the deep involvement of the autonomic nervous system in migraine pathophysiology. The vagus is not simply a passive bystander; it actively participates in the attack by mediating the GI symptoms and may also be involved in the prodromal phase (the warning signs hours before a migraine) through its influence on arousal, appetite, and mood centres.
Cervical nVNS (gammaCore) works by activating vagal afferents that project to the NTS, which then sends inhibitory signals to the TNC. This reduces the trigeminovascular activation driving the pain. The treatment can be used both at the onset of an attack (acute treatment) and as a daily preventive regimen.
Cluster Headache and the Vagus Nerve
Cluster headache is one of the most painful conditions in medicine — severe, unilateral attacks around or behind one eye, occurring in clusters lasting weeks to months. Attacks involve intense activation of the trigeminal-autonomic reflex, producing tearing, nasal congestion, and eyelid drooping on the affected side.
The hypothalamus is considered the primary driver of cluster headache (neuroimaging shows hypothalamic activation during attacks). The vagus nerve’s brainstem connections to hypothalamic nuclei may explain why VNS can interrupt cluster attacks — vagal afferent signals modulate the hypothalamic-brainstem circuit that generates the cluster pattern.
gammaCore’s clinical trials for cluster headache showed particular effectiveness in episodic cluster headache (the form with distinct on/off periods), with less consistent results in chronic cluster headache (attacks year-round without remission). For patients with episodic cluster headache, nVNS offers a drug-free alternative or supplement to oxygen therapy and triptans.
Other Headache Connections
Cervicogenic headache. These headaches originate from the upper cervical spine and neck structures, and the vagus nerve runs through this region in the carotid sheath. Cervical pathology (disc herniation, muscle spasm, fascial compression) can theoretically irritate the vagus nerve, contributing to headache alongside occipital neuralgia. However, the evidence for a direct vagal mechanism in cervicogenic headache is limited compared to migraine and cluster headache.
Post-concussion headache. Emerging research suggests that traumatic brain injury disrupts autonomic function, including vagal tone. Some post-concussion headache patients show reduced HRV, and pilot studies are exploring whether VNS could improve both autonomic regulation and headache frequency after concussion.
Medication-overuse headache. No specific vagal mechanism has been established for medication-overuse headache, but VNS has been explored as a tool to reduce reliance on acute medications by providing a drug-free acute treatment alternative.
Practical Considerations
gammaCore is available by prescription in many countries. It is a handheld device that requires regular purchasing of treatment credits. For patients with frequent migraines or cluster headaches who want to reduce medication use, it offers a genuinely non-pharmacological acute treatment option with a reasonable evidence base. It is not a cure for migraine or cluster headache, and response rates vary — not every patient benefits. The strongest evidence is for acute episodic cluster headache and for acute migraine treatment.
For headache sufferers considering VNS, the starting point is diagnosis. The vagus nerve connection is relevant for primary headache disorders (migraine, cluster headache), not for headaches caused by other conditions (tension-type headache, sinusitis, intracranial pathology). A neurologist or headache specialist can determine whether nVNS is appropriate for a specific headache pattern.
Want the full guide to how the vagus nerve affects headache, pain processing, and what the latest research says about non-invasive VNS? Get the Vagus Nerve & Me eBook for the definitive evidence-based resource.
